Petros Pharmaceuticals is developing the first Over-the-Counter therapeutic option for erectile dysfunction, aiming to increase access to essential medications without the need for a prescription. By transforming prescription drugs into OTC alternatives, the company addresses the significant barriers to medication access faced by millions of households in the United States.
Funding
$7.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Millions of individuals in the United States face barriers to accessing essential medications, often due to the need for a prescription and subsequent doctor visits. This can lead to delayed or forgone treatment, impacting health outcomes and increasing healthcare costs.
Solution
Petros Pharmaceuticals focuses on converting prescription drugs into over-the-counter (OTC) medications to improve accessibility and convenience for consumers. The company's primary focus is on its erectile dysfunction (ED) therapy, seeking FDA approval for OTC designation. If approved, this would make it the first prescription-grade ED treatment available without a prescription, potentially reducing healthcare costs and improving patient access to medication. Petros Pharmaceuticals aims to establish a proven platform for developing other prospective prescription therapeutics for OTC availability.
Target Audience
The primary target audience includes adult men experiencing erectile dysfunction, as well as consumers who prefer the convenience and accessibility of over-the-counter medications.
Features
- Development of prescription-grade therapeutic options for over-the-counter availability.
- Focus on erectile dysfunction (ED) therapy as the initial target for OTC conversion.
- Aims to secure FDA approval for OTC designation of its ED treatment.
- Platform for developing other prescription therapeutics for OTC availability.